Collegium Q3 record revenue $127M (+61% YoY), adj. EPS $1.10, raises FY guidance; completes Xtampza ER renegotiation

COLLEGIUM PHARMACEUTICAL, INC

2022-Q3 EPS reported -$0.52 revenue$334,313,000

Record Q3 revenue $127.0M (+61% YoY); GAAP net income $0.5M ($0.01 EPS), adj. net income $42.5M ($1.10 adj. EPS).
Completed Xtampza ER contract renegotiations; gross-to-net <65% effective Jan 1, 2023, maintaining broad access.
Returned $10M capital via share repurchases ($6.4M in Q3, $3.6M in Oct). $42.1M remains under $100M program.
Updated FY2022 guidance: revenue $455-465M, adj. EBITDA $250-255M, adj. opex $125-130M.
Ended Q3 with $134.1M cash; made $25M debt repayments; BDSI synergy target raised to ~$85M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COLLEGIUM PHARMACEUTICAL, INC reported quarter ended September 30, 2022 results: revenue 127.0 million, net income 0.5 million, EPS 0.01.

Period: quarter ended September 30, 2022
Revenue: 127.0 million
Net income: 0.5 million
EPS: 0.01
Result: reported results

Exact text from the filing

Total net product revenues were $127.0 million for the quarter ended September 30, 2022 (the “2022 Quarter”), compared to $78.8 million for the quarter ended September 30, 2021 (the “2021 Quarter”).

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001558370-22-016231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.